| Original language | English (US) |
|---|---|
| Pages (from-to) | 1501-1502 |
| Number of pages | 2 |
| Journal | Journal of the American College of Cardiology |
| Volume | 75 |
| Issue number | 12 |
| DOIs | |
| State | Published - Mar 31 2020 |
| Externally published | Yes |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American College of Cardiology, Vol. 75, No. 12, 31.03.2020, p. 1501-1502.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reply
T2 - Different Phenotype Characterization in PARAGON-HF: An Unresolved Puzzle in Patients With HFpEF
AU - PARAGON-HF Investigators
AU - Shah, Amil M.
AU - Cikes, Maja
AU - Zile, Michael R.
AU - McMurray, John J.V.
AU - Solomon, Scott D.
N1 - Funding Information: Please note: The PARAGON-HF trial was funded by Novartis. The work for this manuscript was also supported by National Heart, Lung, and Blood Institute grants R01HL135008 and R01HL143224 (to Dr. Shah) and a Watkins Discovery Award from the Brigham and Women's Heart and Vascular Center (to Dr. Shah). Dr. Shah has received research support from Novartis through Brigham and Women's Hospital; and has received consulting fees from Philips Ultrasound and Bellerophon Therapeutics. Dr. Zile has received grants and personal fees from Novartis, CVRx, and Medtronic; and has received personal fees from Abbott, Boston Scientific, EBR, Endotronix, Ironwood, Merck, MyoKardia, and V Wave. Dr. McMurray's employer, Glasgow University, was paid by Novartis for his role as co-principal investigator of PARAGON-HF. Dr. Solomon's employer, Brigham and Women's Hospital, was paid by Novartis for his role as co-principal investigator of PARAGON-HF. Dr. Cikes has reported that she has no relationships relevant to the contents of this paper to disclose. Funding Information: Please note: The PARAGON-HF trial was funded by Novartis. The work for this manuscript was also supported by National Heart, Lung, and Blood Institute grants R01HL135008 and R01HL143224 (to Dr. Shah) and a Watkins Discovery Award from the Brigham and Women’s Heart and Vascular Center (to Dr. Shah). Dr. Shah has received research support from Novartis through Brigham and Women’s Hospital; and has received consulting fees from Philips Ultrasound and Bellerophon Therapeutics. Dr. Zile has received grants and personal fees from Novartis, CVRx, and Medtronic; and has received personal fees from Abbott, Boston Scientific, EBR, Endotronix, Ironwood, Merck, MyoKardia, and V Wave. Dr. McMurray’s employer, Glasgow University, was paid by Novartis for his role as co-principal investigator of PARAGON-HF. Dr. Solomon’s employer, Brigham and Women’s Hospital, was paid by Novartis for his role as co-principal investigator of PARAGON-HF. Dr. Cikes has reported that she has no relationships relevant to the contents of this paper to disclose.
PY - 2020/3/31
Y1 - 2020/3/31
UR - http://www.scopus.com/inward/record.url?scp=85081659889&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081659889&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2020.01.028
DO - 10.1016/j.jacc.2020.01.028
M3 - Letter
C2 - 32216926
AN - SCOPUS:85081659889
SN - 0735-1097
VL - 75
SP - 1501
EP - 1502
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 12
ER -